

Special Issue

Precision Medicine in Breast Cancer: From Basic Research to Clinical Practice

Message from the Guest Editors

Precision medicine (PM) has become the modern-day approach to breast cancer management. Depending on the genetic variations, environmental factors, and lifestyle dynamics of each individual, PM aims to accomplish optimal therapeutic results, with reduced or no side effects, in a reasonable time and at an appropriate cost. The approach of PM to disease management has been driven by the evolution of molecular biology and the opening of the human genome. PM is applied to most branches of medicine, including oncology, preventive medicine, and genetic and inherited disease, and there are no ethical dilemmas or moral challenges related to PM.

Guest Editors

Dr. Yong Wu

1. Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA
2. David Geffen UCLA School of Medicine, Los Angeles, CA, USA
3. UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

Dr. John Yahya I. Elshimali

Division of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science & UCLA School of Medicine, Los Angeles, CA, USA

Deadline for manuscript submissions

10 December 2024



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/179482

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).